The Conversation (0)
Aquinox Pharmaceuticals Inc announced that it has secured US $18 million of a Series C financing led by Johnson&Johnson Development Corp. The company will use the proceeds to build upon the success of its recently concluded Phase IIa clinical studies for AQX-1125 and SHIP1 activator program as treatment of inflammatory disease.
Aquinox Pharmaceuticals Inc announced that it has secured US $18 million of a Series C financing led by Johnson&Johnson Development Corp. The company will use the proceeds to build upon the success of its recently concluded Phase IIa clinical studies for AQX-1125 and SHIP1 activator program as treatment of inflammatory disease.
As quoted in the press release:
New investor Augment Investments Ltd. participated in the financing along with existing investors: Pfizer Venture Investments, Ventures West Capital, and Baker Brothers Investments.
“The strong support from our existing investors, together with the addition of Augment Investments, puts us in an enviable position to continue to build on our global leadership position with our new class of anti-inflammatory drugs,” stated Mr. David Main, President and CEO of Aquinox.
Click here to read the full Aquinox Pharmaceuticals Inc press release.
